CP-25, a compound derived from paeoniflorin: research advance on its pharmacological actions and mechanisms in the treatment of inflammation and immune diseases
CP-25, a compound derived from paeoniflorin: research advance on its pharmacological actions and mechanisms in the treatment of inflammation and immune diseases
复制标题
芍药甙化合物CP-25治疗炎症和免疫疾病的药理作用及机制研究进展
DOI：
10.1038/s41401-020-00510-6
复制
发表时间：
2020-09
期刊：
影响因子：
--
通讯作者：
Wei Wei
中科院分区：
文献类型：
--
作者：
Xuezhi Yang;Wei Wei
白芍总苷在中国医案中被广泛用于治疗炎症和免疫性疾病。白芍总苷(Pae)是白藜芦醇苷的主要活性成分。尽管TGP的不良反应很少，但其起效慢，生物利用度低，限制了其临床应用。在开发治疗炎症和免疫疾病的新药物时，人们追求在不增加毒性的情况下提高疗效。因此，本课题组自行研制开发了从PAE衍生而来的芍药苷-6‘-O-苯磺酸盐(CP-25)，其生物利用度和药效均优于PAE。本文介绍了CP-25的开发过程和研究进展。比较了CP-25和Pae在体内和体外的药代动力学参数。CP-25还与一线药物甲氨蝶呤、来氟米特和羟氯喹在关节炎动物模型和实验性干燥综合征中的疗效和不良反应进行了比较。我们总结了CP-25对炎症和免疫相关细胞的调节作用，阐明了可能的机制，并分析了CP-25在炎症和免疫疾病以及与其潜在靶点G蛋白偶联受体激酶2(GRK2)相关的疾病中的治疗前景。同时，本综述为抗炎免疫药物的开发提供了新的思路。
Total glycoside of paeony (TGP) has been widely used to treat inflammation and immune diseases in China. Paeoniflorin (Pae) is the major active component of TGP. Although TGP has few adverse drug reactions, the slow onset and low bioavailability of Pae limit its clinical use. Enhanced efficacy without increased toxicity is pursued in developing new agents for inflammation and immune diseases. As a result, paeoniflorin-6′-O-benzene sulfonate (CP-25) derived from Pae, is developed in our group, and exhibits superior bioavailability and efficacy than Pae. Here we describe the development process and research advance on CP-25. The pharmacokinetic parameters of CP-25 and Pae were compared in vivo and in vitro. CP-25 was also compared with the first-line drugs methotrexate, leflunomide, and hydroxychloroquine in their efficacy and adverse effects in arthritis animal models and experimental Sjögren’s syndrome. We summarize the regulatory effects of CP-25 on inflammation and immune-related cells, elucidate the possible mechanisms, and analyze the therapeutic prospects of CP-25 in inflammation and immune diseases, as well as the diseases related to its potential target G-protein-coupled receptor kinases 2 (GRK2). This review suggests that CP-25 is a promising agent in the treatment of inflammation and immune diseases, which requires extensive investigation in the future. Meanwhile, this review provides new ideas about the development of anti-inflammatory immune drugs.
登录
查看更多内容
类风湿性关节炎患者的成纤维样滑膜细胞上表达的免疫球蛋白 D Fc 受体有助于细胞活化
影响因子：
8.2
作者：
Wu Yu-jing;Chen Wen-sheng;Chen Heng-shi;Dai Xing;Dong Jin;Wang Ying;Zhang Ling-ling;Chang Yan;Huang Qiong;Jia Xiao-yi;Wei Wei;Wei W
通讯作者：
Wei W
DOI：
10.1016/j.rdc.2016.03.010
发表时间：
2016-08
期刊：
Rheumatic diseases clinics of North America
影响因子：
--
作者：
Vivino FB;Carsons SE;Foulks G;Daniels TE;Parke A;Brennan MT;Forstot SL;Scofield RH;Hammitt KM
通讯作者：
Hammitt KM
影响因子：
4.6
作者：
Wang Q;Wang L;Wu L;Zhang M;Hu S;Wang R;Han Y;Wu Y;Zhang L;Wang X;Sun W;Wei W
通讯作者：
Wei W
芍药苷 CP-25 的修饰化合物可抑制胶原诱导的关节炎小鼠的免疫反应和滑膜炎症。
影响因子：
5.6
作者：
Chen J;Wang Y;Wu H;Yan S;Chang Y;Wei W
通讯作者：
Wei W
影响因子：
3.4
作者：
Min Zhang;Mei Gao;Jinyue Chen;Li-hua Song;Wei Wei-Wei
通讯作者：
Min Zhang;Mei Gao;Jinyue Chen;Li-hua Song;Wei Wei-Wei